FENOFIBRATE Side Effects

6790267-7 | Erythema Multiforme
on Jun 16, 2010 Female patient from JAPAN , 68 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: erythema multiforme. Fenofibrate dosage: . During the same period patient was treated with ROSUVASTATIN CALCIUM (View Rosuvastatin Calcium Review and Rosuvastatin Calcium Label ).

6786183-7 | Arrhythmia, Bone Pain, Musculoskeletal Pain, Pollakiuria
Patient was taking Fenofibrate (View Usage). Patient had the following side effects: arrhythmia (What is arrhythmia?), bone pain, musculoskeletal pain, pollakiuria on Jun 22, 2010 from UNITED STATES Additional patient health information: Female patient , 73 years of age, weighting 220.0 lb, was diagnosed with blood triglycerides increased and. Fenofibrate dosage: One Daily Po.

6784252-9 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Albumin Decreased, Blood Calcium Decreased, Blood Lactate Dehydrogenase Increased, Blood Ph Decreased, Blood Potassium Increased, Haemoglobin Decreased, Po2 Decreased
Adverse event was reported on Jun 07, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: 200 Mg, Daily (15 Days Prior To Presenting)) was diagnosed with hyperlipidaemia and. Location: TURKEY , 74 years of age, After Fenofibrate was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood albumin decreased, blood calcium decreased, blood lactate dehydrogenase increased, blood ph decreased, blood potassium increased, haemoglobin decreased, po2 decreased.

6784226-8 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Creatinine Increased, Blood Lactate Dehydrogenase Increased, Blood Potassium Increased, Blood Urea Increased, Chest Pain, Haemoglobin Decreased, Kidney Small
on Jun 07, 2010 Male patient from TURKEY , 69 years of age, was diagnosed with hypertriglyceridaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood creatinine increased, blood lactate dehydrogenase increased, blood potassium increased, blood urea increased, chest pain (What is chest pain?), haemoglobin decreased, kidney small. Fenofibrate dosage: 200 Mg Daily (3 Months Prior To Diagnosis).


6782691-3 | Hepatic Function Abnormal
on Jun 11, 2010 Male patient from JAPAN , 60 years of age, was diagnosed with low density lipoprotein increased and was treated with Fenofibrate (View Usage). Patient had the following side effects: hepatic function abnormal. Fenofibrate dosage: 134mg Daily. During the same period patient was treated with DILTIAZEM HYDROCHLORIDE (View Diltiazem Hydrochloride Review and Diltiazem Hydrochloride Label ), DAI KENCHU TO (View Dai-kenchu-to Review and Dai-kenchu-to Label ), SENNA LEAF (View Senna Leaf Review and Senna Leaf Label ), FLUVASTATIN SODIUM (View Fluvastatin Sodium Review and Fluvastatin Sodium Label ).

6780339-5 | Jaundice, Liver Disorder
Patient was taking Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: jaundice (What is jaundice?), liver disorder on Jun 08, 2010 from GERMANY Additional patient health information: Male patient , 71 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: . During the same period patient was treated with FLUVASTATIN SODIUM (View Fluvastatin Sodium Review and Fluvastatin Sodium Label ), GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ), VALSARTAN (View Valsartan Review and Valsartan Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

6773661-X | Renal Failure Acute, Rhabdomyolysis
Adverse event was reported on Jun 02, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: ) was diagnosed with hypertriglyceridaemia, hypertension and. Location: TURKEY , 69 years of age, Patient experienced the following unwanted or unexpected effects: renal failure acute, rhabdomyolysis. During the same period patient was treated with AMLODIPINE (View Amlodipine Review and Amlodipine Label ), METOPROLOL (View Metoprolol Review and Metoprolol Label ), DIOVAN HCT (Valsartan 160mg/ Hydrochlorothiazide 25mg) (View Diovan Hct Review and Diovan Hct Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

6773660-8 | Renal Failure Acute, Rhabdomyolysis
on Jun 02, 2010 Male patient from TURKEY , 74 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient had the following side effects: renal failure acute, rhabdomyolysis. Fenofibrate dosage: . Patient was hospitalized.

6765507-0 | Renal Failure Acute, Rhabdomyolysis
on May 28, 2010 Male patient from TURKEY , 69 years of age, was diagnosed with hypertriglyceridaemia and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: renal failure acute, rhabdomyolysis. Fenofibrate dosage: 200 Mg, Unk.

6765493-3 | Renal Failure Acute, Rhabdomyolysis
Patient was taking Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure acute, rhabdomyolysis on May 28, 2010 from TURKEY Additional patient health information: Male patient , 74 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: 200 Mg, Unk.

6750822-7 | Jaundice, Liver Disorder
Adverse event was reported on May 12, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: 200 Mg, Unk) was diagnosed with hyperlipidaemia and. Location: JAPAN , 71 years of age, Patient had the following side effects: jaundice (What is jaundice?), liver disorder. During the same period patient was treated with FLUVASTATIN SODIUM (View Fluvastatin Sodium Review and Fluvastatin Sodium Label ), GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ), VALSARTAN (View Valsartan Review and Valsartan Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

6746450-X | Herpes Zoster, Renal Failure Acute
on May 15, 2010 Male patient from JAPAN , 63 years of age, was diagnosed with hyperlipidaemia, herpes zoster and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: herpes zoster, renal failure acute. Fenofibrate dosage: Unk. During the same period patient was treated with LOXOPROFEN SODIUM (Unk) (View Loxoprofen Sodium Review and Loxoprofen Sodium Label ), ACYCLOVIR (Unk) (View Acyclovir Review and Acyclovir Label ), VALACYCLOVIR (Unk) (View Valacyclovir Review and Valacyclovir Label ), BENZBROMARONE (Unk) (View Benzbromarone Review and Benzbromarone Label ), POTASSIUM CITRATE, SODIUM CITRATE (Unk) (View Potassium Citrate, Sodium Citrate Review and Potassium Citrate, Sodium Citrate Label ), PROBUCOL (Unk) (View Probucol Review and Probucol Label ), PRAVASTATIN SODIUM (Unk) (View Pravastatin Sodium Review and Pravastatin Sodium Label ). Patient was hospitalized.

6744958-4 | Jaundice, Liver Disorder
on May 17, 2010 Male patient from GERMANY , 71 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: jaundice (What is jaundice?), liver disorder. Fenofibrate dosage: . During the same period patient was treated with FLUVASTATIN SODIUM (View Fluvastatin Sodium Review and Fluvastatin Sodium Label ), GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ), VALSARTAN (View Valsartan Review and Valsartan Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

6741548-4 | Herpes Zoster, Renal Failure
Patient was taking Fenofibrate (View Usage). Patient had the following side effects: herpes zoster, renal failure on May 14, 2010 from GERMANY Additional patient health information: Male patient , 63 years of age, was diagnosed with hyperlipidaemia, herpes zoster and. Fenofibrate dosage: . During the same period patient was treated with LOXOPROFEN SODIUM (View Loxoprofen Sodium Review and Loxoprofen Sodium Label ), ACYCLOVIR SODIUM (View Acyclovir Sodium Review and Acyclovir Sodium Label ), VALACYCLOVIR (View Valacyclovir Review and Valacyclovir Label ), BENZBROMARONE (View Benzbromarone Review and Benzbromarone Label ), POTASSIUM CITRATE (View Potassium Citrate Review and Potassium Citrate Label ), PROBUCOL (View Probucol Review and Probucol Label ), PRAVASTATIN SODIUM (View Pravastatin Sodium Review and Pravastatin Sodium Label ). Patient was hospitalized.

6719587-9 | Headache
Adverse event was reported on May 10, 2010 by a Female patient taking Fenofibrate (View Usage) (Dosage: 1 Tablet Daily Po) was diagnosed with blood cholesterol increased and. Location: UNITED STATES , 65 years of age, weighting 150.0 lb, After Fenofibrate was administered, patient had the following side effects: headache (What is headache?).

6719435-7 | Rhabdomyolysis
on May 10, 2010 Male patient from UNITED STATES , 74 years of age, weighting 195.1 lb, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: rhabdomyolysis. Fenofibrate dosage: 48 Mg Every Day Po. During the same period patient was treated with PRAVASTATIN (40 Mg Hs Po) (View Pravastatin Review and Pravastatin Label ). Patient was hospitalized.

6716638-2 | Liver Function Test Abnormal
on Apr 29, 2010 Male patient from GERMANY , 54 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient had the following side effects: liver function test abnormal. Fenofibrate dosage: 100mg Daily. During the same period patient was treated with EZETIMIBE (10mg Daily) (View Ezetimibe Review and Ezetimibe Label ), MIGLITOL (View Miglitol Review and Miglitol Label ), AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), VALSARTAN (View Valsartan Review and Valsartan Label ).

6714422-7 | Liver Function Test Abnormal
Patient was taking Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: liver function test abnormal on Apr 28, 2010 from JAPAN Additional patient health information: Male patient , 55 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: 134mg Daily. During the same period patient was treated with GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ), MIGLITOL (View Miglitol Review and Miglitol Label ), PIOGLITAZONE HYDROCHLORIDE (View Pioglitazone Hydrochloride Review and Pioglitazone Hydrochloride Label ).

6711973-6 | Pollakiuria, Renal Impairment
Adverse event was reported on Apr 26, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: ) was diagnosed with hypertriglyceridaemia, rhinitis allergic, vitamin supplementation and. Location: UNITED STATES , 47 years of age, Patient experienced the following unwanted or unexpected effects: pollakiuria, renal impairment. During the same period patient was treated with ZYRTEC (View Zyrtec Review and Zyrtec Label ), POPON S (View Popon S Review and Popon S Label ).

6710775-4 | Liver Disorder
on Apr 20, 2010 Male patient from GERMANY , 55 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient had the following side effects: liver disorder. Fenofibrate dosage: 134 Mg, Unk. During the same period patient was treated with GLIMEPIRIDE (Unk) (View Glimepiride Review and Glimepiride Label ), MIGLITOL (Unk) (View Miglitol Review and Miglitol Label ), PIOGLITAZONE (Unk) (View Pioglitazone Review and Pioglitazone Label ).

6708839-4 | Blood Creatine Phosphokinase Increased, Blood Lactate Dehydrogenase Increased, Hypothyroidism, Swelling Face
on Apr 20, 2010 Male patient from JAPAN , 60 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: blood creatine phosphokinase increased, blood lactate dehydrogenase increased, hypothyroidism, swelling face. Fenofibrate dosage: 100 Mg, Unk. During the same period patient was treated with SENNOSIDE (Unk) (View Sennoside Review and Sennoside Label ).

6701411-1 | Renal Failure Acute, Rhabdomyolysis
Patient was taking Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure acute, rhabdomyolysis on Apr 15, 2010 from GERMANY Additional patient health information: Male patient , 52 years of age, . Fenofibrate dosage: .

6697606-6 | Liver Disorder
Adverse event was reported on Apr 16, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: 134mg Daily) was diagnosed with hyperlipidaemia and. Location: GERMANY , 55 years of age, Patient had the following side effects: liver disorder. During the same period patient was treated with GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ), MIGLITOL (View Miglitol Review and Miglitol Label ), PIOGLITAZONE HYDROCHLORIDE (View Pioglitazone Hydrochloride Review and Pioglitazone Hydrochloride Label ).

6695499-4 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Triglycerides Increased, Hypoaesthesia, Liver Function Test Abnormal
on Apr 12, 2010 Female patient from GERMANY , 62 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood triglycerides increased, hypoaesthesia, liver function test abnormal. Fenofibrate dosage: 200 Mg, Unk. During the same period patient was treated with NIFEDIPINE (Unk) (View Nifedipine Review and Nifedipine Label ), ASPIRIN (Unk) (View Aspirin Review and Aspirin Label ), EZETIMIBE (Unk) (View Ezetimibe Review and Ezetimibe Label ).

6693695-3 | Renal Failure Acute, Rhabdomyolysis
on Apr 09, 2010 Male patient from GERMANY , 74 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure acute, rhabdomyolysis. Fenofibrate dosage: 200 Mg, Unk.

6692370-9 | Muscle Spasms, Rhabdomyolysis
Patient was taking Fenofibrate (View Usage). Patient had the following side effects: muscle spasms, rhabdomyolysis on Feb 01, 2010 from CANADA Additional patient health information: Male patient , 67 years of age, was diagnosed with hyperlipidaemia, prostatomegaly, gastrooesophageal reflux disease and. Fenofibrate dosage: 160 Mg;qd;po. During the same period patient was treated with TERAZOSIN HCL (4 Tab;qd;po) (View Terazosin Hcl Review and Terazosin Hcl Label ), RANITIDINE (150 Mg;bid;po) (View Ranitidine Review and Ranitidine Label ), SILDENAFIL CITRATE (View Sildenafil Citrate Review and Sildenafil Citrate Label ), EZETIMIBE (View Ezetimibe Review and Ezetimibe Label ), CLOPIDOGREL BISULFATE (View Clopidogrel Bisulfate Review and Clopidogrel Bisulfate Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), DILTIAZEM HCL (View Diltiazem Hcl Review and Diltiazem Hcl Label ), RAMIPRIL (View Ramipril Review and Ramipril Label ).

6692361-8 | Muscle Spasms, Rhabdomyolysis
Adverse event was reported on Feb 01, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: 160 Mg;tab;po;qd 15 Mg;tab;po;qd) was diagnosed with gastrooesophageal reflux disease, hyperlipidaemia and. Location: CANADA , 67 years of age, After Fenofibrate was administered, patient had the following side effects: muscle spasms, rhabdomyolysis. During the same period patient was treated with SILDENAFIL CITRATRE (SILDENAFIL CITRATE) (View Sildenafil Citratre (sildenafil Citrate) Review and Sildenafil Citratre (sildenafil Citrate) Label ), EZETIMIBE (View Ezetimibe Review and Ezetimibe Label ), CLOPIDOGREL BISULFATE (View Clopidogrel Bisulfate Review and Clopidogrel Bisulfate Label ).

6691322-2 | Renal Failure, Rhabdomyolysis
on Apr 08, 2010 Male patient from GERMANY , 69 years of age, was diagnosed with hypertriglyceridaemia, hypertension and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure, rhabdomyolysis. Fenofibrate dosage: 200 Mg, Unk. During the same period patient was treated with AMLODIPINE (10 Mg, Unk) (View Amlodipine Review and Amlodipine Label ), METOPROLOL TARTRATE (50 Mg, Unk) (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), VALSARTAN/HYDROCHLOROTHIAZIDE COMBINATION (160 MG + 25 MG) (View Valsartan/hydrochlorothiazide Combination (160 Mg + 25 Mg) Review and Valsartan/hydrochlorothiazide Combination (160 Mg + 25 Mg) Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

6690992-2 | Hypothyroidism
on Apr 15, 2010 Male patient from GERMANY , 60 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient had the following side effects: hypothyroidism. Fenofibrate dosage: . During the same period patient was treated with SENNOSIDE (View Sennoside Review and Sennoside Label ).

6686903-6 | Abasia, Cardiac Failure Congestive, Dyspnoea, Kidney Small, Muscular Weakness
Patient was taking Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: abasia, cardiac failure congestive, dyspnoea, kidney small, muscular weakness on Apr 16, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 172.0 lb, . Fenofibrate dosage: One Daily. Patient was hospitalized.

6686830-4 | Abdominal Distension, Abdominal Pain Upper, Condition Aggravated, Flatulence, Tendonitis
Adverse event was reported on Apr 16, 2010 by a Female patient taking Fenofibrate (View Usage) (Dosage: 200 Mg 1/day By Mouth) was diagnosed with blood triglycerides increased and. Location: UNITED STATES , weighting 172.4 lb, Patient experienced the following unwanted or unexpected effects: abdominal distension, abdominal pain upper, condition aggravated, flatulence, tendonitis.

6682604-9 | Liver Function Test Abnormal
on Apr 08, 2010 Female patient from GERMANY , 74 years of age, was diagnosed with dyslipidaemia and was treated with Fenofibrate (View Usage). Patient had the following side effects: liver function test abnormal. Fenofibrate dosage: 100mg Daily. During the same period patient was treated with CANDESARTAN CILEXETIL (View Candesartan Cilexetil Review and Candesartan Cilexetil Label ), BENIDIPINE HYDROCHLORIDE (View Benidipine Hydrochloride Review and Benidipine Hydrochloride Label ), CEFDINIR (View Cefdinir Review and Cefdinir Label ), NON PYRINE COLD PREPARATION (View Non-pyrine Cold Preparation Review and Non-pyrine Cold Preparation Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ).

6678760-9 | Hepatic Function Abnormal
on Mar 30, 2010 Male patient from GERMANY , 57 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: hepatic function abnormal. Fenofibrate dosage: 200 Mg, Unk. During the same period patient was treated with ALLOPURINOL (Unk) (View Allopurinol Review and Allopurinol Label ), ETHYL ISOSAPENTATE (Unk) (View Ethyl Isosapentate Review and Ethyl Isosapentate Label ).

6676579-6 | Hepatic Function Abnormal
Patient was taking Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic function abnormal on Mar 30, 2010 from GERMANY Additional patient health information: Male patient , 57 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: . During the same period patient was treated with ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), ETHYL ICOSAPENTATE (View Ethyl Icosapentate Review and Ethyl Icosapentate Label ).

6676042-2 | Blood Creatine Phosphokinase Increased, Liver Function Test Abnormal
Adverse event was reported on Mar 29, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: 1 Df, Unk) . Location: GERMANY , 71 years of age, Patient had the following side effects: blood creatine phosphokinase increased, liver function test abnormal. During the same period patient was treated with CRESTOR (View Crestor Review and Crestor Label ), EZETROL (View Ezetrol Review and Ezetrol Label ), NORVASC (View Norvasc Review and Norvasc Label ).

6675002-5 | Hepatic Function Abnormal
on Mar 30, 2010 Male patient from GERMANY , 59 years of age, was diagnosed with hyperlipidaemia, diabetes mellitus and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: hepatic function abnormal. Fenofibrate dosage: . During the same period patient was treated with VOGLIBOSE (View Voglibose Review and Voglibose Label ), GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ).

6666552-6 | Hepatic Function Abnormal
on Mar 25, 2010 Male patient from GERMANY , 58 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic function abnormal. Fenofibrate dosage: 134 Mg Daily. During the same period patient was treated with ALLOPURINOL (200 Mg Daily) (View Allopurinol Review and Allopurinol Label ), REBAMIPIDE (300 Mg Daily) (View Rebamipide Review and Rebamipide Label ), LACTOMIN (6 Gm Daily) (View Lactomin Review and Lactomin Label ).

6662867-6 | Blood Creatine Phosphokinase Increased, Hypothyroidism, Swelling Face
Patient was taking Fenofibrate (View Usage). Patient had the following side effects: blood creatine phosphokinase increased, hypothyroidism, swelling face on Mar 18, 2010 from JAPAN Additional patient health information: Male patient , 60 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: 100 Mg, Unk. During the same period patient was treated with SENNOSIDE (Unk) (View Sennoside Review and Sennoside Label ).

6660331-1 | Photosensitivity Reaction, Skin Exfoliation
Adverse event was reported on Mar 18, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: 200 Mg, Unk) was diagnosed with hypercholesterolaemia and. Location: UNITED KINGDOM , 63 years of age, After Fenofibrate was administered, patient had the following side effects: photosensitivity reaction, skin exfoliation. During the same period patient was treated with ASPIRIN (75 Mg, Unk) (View Aspirin Review and Aspirin Label ), BISOPROLOL (10 Mg, Unk) (View Bisoprolol Review and Bisoprolol Label ), CITALOPRAM HYDROBROMIDE (40 Mg, Unk) (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), EZETIMIBE (10 Mg, Qd) (View Ezetimibe Review and Ezetimibe Label ), LISINOPRIL (10 Mg, Unk) (View Lisinopril Review and Lisinopril Label ), QUESTRAN (2 Df, Bid) (View Questran Review and Questran Label ).

6656900-5 | Blood Creatine Increased, Blood Creatine Phosphokinase Increased, Blood Urea Increased, Brain Natriuretic Peptide Increased, Myalgia, Renal Failure, Rhabdomyolysis
on Mar 29, 2010 Male patient from UNITED STATES , 64 years of age, weighting 244.7 lb, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatine increased, blood creatine phosphokinase increased, blood urea increased, brain natriuretic peptide increased, myalgia, renal failure, rhabdomyolysis. Fenofibrate dosage: 1 Tab Every Day Po. During the same period patient was treated with ROSUVASTATIN (20 Mg Every Day Po) (View Rosuvastatin Review and Rosuvastatin Label ). Patient was hospitalized.

6656189-7 | Photosensitivity Reaction, Skin Exfoliation
on Mar 19, 2010 Male patient from GERMANY , 63 years of age, was diagnosed with hypercholesterolaemia and was treated with Fenofibrate (View Usage). Patient had the following side effects: photosensitivity reaction, skin exfoliation. Fenofibrate dosage: . During the same period patient was treated with QUESTRAN (View Questran Review and Questran Label ), EZETIMIBE (View Ezetimibe Review and Ezetimibe Label ), BISOPROLOL (View Bisoprolol Review and Bisoprolol Label ), CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

6652571-2 | Hepatic Function Abnormal
Patient was taking Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: hepatic function abnormal on Mar 11, 2010 from GERMANY Additional patient health information: Male patient , 57 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: Unk. During the same period patient was treated with ALLOPURINOL (Unk) (View Allopurinol Review and Allopurinol Label ).

6652252-5 | Renal Impairment
Adverse event was reported on Mar 16, 2010 by a Male patient taking Fenofibrate (View Usage) (Dosage: ) was diagnosed with hypertriglyceridaemia and. Location: GERMANY , 74 years of age, Patient experienced the following unwanted or unexpected effects: renal impairment. During the same period patient was treated with LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (View Losartan Potassium And Hydrochlorothiazide Review and Losartan Potassium And Hydrochlorothiazide Label ), OLMESARTAN MEDOXOMIL (View Olmesartan Medoxomil Review and Olmesartan Medoxomil Label ), BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), CLOPIDOGREL SULFATE (View Clopidogrel Sulfate Review and Clopidogrel Sulfate Label ), IFENPRODIL TARTRATE (View Ifenprodil Tartrate Review and Ifenprodil Tartrate Label ), ADENOSINE TRIPHOSPHATE, DISODIUM SALT (View Adenosine Triphosphate, Disodium Salt Review and Adenosine Triphosphate, Disodium Salt Label ), CARBOCISTEINE (View Carbocisteine Review and Carbocisteine Label ).

6647756-5 | Hepatic Function Abnormal
on Mar 15, 2010 Female patient from GERMANY , 74 years of age, was diagnosed with dyslipidaemia and was treated with Fenofibrate (View Usage). Patient had the following side effects: hepatic function abnormal. Fenofibrate dosage: 100mg Daily. During the same period patient was treated with CANDESARTAN CILEXETIL (View Candesartan Cilexetil Review and Candesartan Cilexetil Label ), BENIDIPINE HYDROCHLORIDE (View Benidipine Hydrochloride Review and Benidipine Hydrochloride Label ), CEFDINIR (View Cefdinir Review and Cefdinir Label ), NON PYRINE COLD PREPARATION (View Non-pyrine Cold Preparation Review and Non-pyrine Cold Preparation Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ).

6637848-9 | Hepatic Function Abnormal
on Mar 11, 2010 Male patient from GERMANY , 57 years of age, was diagnosed with hyperlipidaemia and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: hepatic function abnormal. Fenofibrate dosage: . During the same period patient was treated with ALLOPURINOL (View Allopurinol Review and Allopurinol Label ).

6637596-5 | Renal Impairment
Patient was taking Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: renal impairment on Mar 03, 2010 from GERMANY Additional patient health information: Male patient , 74 years of age, was diagnosed with hypertriglyceridaemia and. Fenofibrate dosage: 100 Mg, Unk. During the same period patient was treated with LOSARTAN POTASSIUM HYDROCHLOROTHIAZIDE (View Losartan Potassium-hydrochlorothiazide Review and Losartan Potassium-hydrochlorothiazide Label ), OLMESARTAN MEDOXOMIL (View Olmesartan Medoxomil Review and Olmesartan Medoxomil Label ), BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), CLOPIDOGREL SULFATE (View Clopidogrel Sulfate Review and Clopidogrel Sulfate Label ), IFENPRODIL TARTRATE (View Ifenprodil Tartrate Review and Ifenprodil Tartrate Label ), ADENOSINE TRIPHOSPHATE DISODIUM (View Adenosine Triphosphate Disodium Review and Adenosine Triphosphate Disodium Label ), CARBOCISTEINE (View Carbocisteine Review and Carbocisteine Label ).

6637595-3 | Dyspnoea, Pharyngeal Haematoma
Adverse event was reported on Mar 03, 2010 by a Female patient taking Fenofibrate (View Usage) (Dosage: ) was diagnosed with dyslipidaemia and. Location: FRANCE , 50 years of age, Patient had the following side effects: dyspnoea, pharyngeal haematoma. During the same period patient was treated with PREVISCAN (View Previscan Review and Previscan Label ). Patient was hospitalized.

6632136-9 | Renal Impairment
on Mar 03, 2010 Male patient from GERMANY , 74 years of age, was diagnosed with hypertriglyceridaemia and was treated with Fenofibrate (View Usage). After Fenofibrate was administered, patient had the following side effects: renal impairment. Fenofibrate dosage: . During the same period patient was treated with LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (View Losartan Potassium And Hydrochlorothiazide Review and Losartan Potassium And Hydrochlorothiazide Label ), OLMESARTAN MEDOXOMIL (View Olmesartan Medoxomil Review and Olmesartan Medoxomil Label ), BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), CLOPIDOGREL SULFATE (View Clopidogrel Sulfate Review and Clopidogrel Sulfate Label ), IFENPRODIL TARTRATE (View Ifenprodil Tartrate Review and Ifenprodil Tartrate Label ), ADENOSINE TRIPHOSPHATE, DISODIUM SALT (View Adenosine Triphosphate, Disodium Salt Review and Adenosine Triphosphate, Disodium Salt Label ), CARBOCISTEINE (View Carbocisteine Review and Carbocisteine Label ).

6631045-9 | Dyspnoea, Haemorrhage, Overdose, Pharyngeal Haematoma
on Mar 03, 2010 Female patient from FRANCE , 50 years of age, was diagnosed with dyslipidaemia, arterial disorder and was treated with Fenofibrate (View Usage). Patient experienced the following unwanted or unexpected effects: dyspnoea, haemorrhage, overdose, pharyngeal haematoma. Fenofibrate dosage: . During the same period patient was treated with VITAMIN K TAB (View Vitamin K Tab Review and Vitamin K Tab Label ), KASKADIL (View Kaskadil Review and Kaskadil Label ). Patient was hospitalized.

6626543-8 | Hepatic Function Abnormal
Patient was taking Fenofibrate (View Usage). Patient had the following side effects: hepatic function abnormal on Mar 04, 2010 from GERMANY Additional patient health information: Male patient , 57 years of age, was diagnosed with hyperlipidaemia and. Fenofibrate dosage: . During the same period patient was treated with ALLOPURINOL (View Allopurinol Review and Allopurinol Label ).